Q1: 2026-05-05 Earnings Summary
EPS of $0.48 beats by $0.09
| Revenue of $194.26M (14.83% Y/Y) beats by $1.91M
Repligen Corporation (RGEN) Bank of America Global Healthcare Conference 2026 May 12, 2026 1:00 PM EDT
Company Participants
Jason Garland – CFO & Chief Compliance Officer
Jacob Johnson – Vice President of Investor Relations
Conference Call Participants
Michael Ryskin – BofA Securities, Research Division
Presentation
Michael Ryskin
BofA Securities, Research Division
We’re excited to host Repligen for our next fireside chat. I joined by Jason Garland, Chief Financial Officer; and Jacob Johnson, IR. And with that, we’ll kick things off. We’re going to do just a fireside chat. If you’ve got questions, throw up your hand, and we’ll try to call on you when we can.
Question-and-Answer Session
Michael Ryskin
BofA Securities, Research Division
Maybe just to kick things off, you guys recently reported 1Q just a couple of weeks ago. Maybe give us a high-level rundown of how the quarter played out relative to expectations, sort of what was a little bit better, what was a little bit surprising? Any key takeaways there?
Jason Garland
CFO & Chief Compliance Officer
Yes. Look, we started the year in a view — in our view, executing exactly what we set out to do, right? So we had a strong first quarter, better than expectations, certainly on a top line basis as well as earnings. It was right down in the middle of the fairway for our overall total year guide on organic growth. So it started strong on the top line and enough confidence in our margin profile that we actually raised EPS guidance for the year. So financially, a great start.
Second, I’d say that we — it helped build that confidence in our total year guide as well. We look at, again, first quarter, 11%. We’ve shared that second quarter is going to be around the same. That’s right in line with our total year guide and which
